CV

Your LinkedIn doesn't need to be perfect – four ways to build an authentic profile to boost your personal brand

Retrieved on: 
Friday, June 2, 2023
Learning, Industry, Generation Z, CV, Failure, Gen, Life, Friends, Professional, Generation, Woman, Attention, Privacy, Language, Student, Risk, Procrastination, Quarterlife, Google, CVS, Mental health, Family, Social media, Nursing, Online shopping, Employment agency, Tourism

But if you’ve spent any time on LinkedIn, you’ll know it’s something anyone can develop with well-crafted posts and engagement.

Key Points: 
  • But if you’ve spent any time on LinkedIn, you’ll know it’s something anyone can develop with well-crafted posts and engagement.
  • In recent years, students and young professionals have turned personal branding into a tool for success in competitive, global job markets.
  • A personal brand is about both how you differentiate yourself from others, and about how others perceive you.
  • We also spoke with recruiters and a career advisor about creating personal brands on LinkedIn.

1. Stay up to date

    • They use these profiles to evaluate potential hires’ talents and professional skills, but also their fit with company culture.
    • The more current and detailed your profile is, the easier it will be for the right employer to find you.

2. Don’t leave out your weaknesses

    • But our interviews reveal that taking the risk to showcase your weaknesses and imperfections can pay off.
    • Participants told us that these posts are popular with followers, help generate conversations, and result in stronger personal brands.
    • The post attracted hundreds of likes and comments, including advice, encouragement and similar stories from people in her network.

3. Engage with others

    • You should initiate conversations, collect thoughts and gather feedback from others in your field.
    • As one student told us:
      We’re all developing, and I don’t want to show employers a perfect, yet not ‘me’ image.
    • We’re all developing, and I don’t want to show employers a perfect, yet not ‘me’ image.

4. Keep your personal life separate

    • It is important to set clear boundaries between your work and private life, and make good use of privacy settings to maintain your personal brand.
    • Your posts on professional sites can be personal, but from a professional context and not something you don’t want recruiters to see – for example, photos that show you partying.

Metcal Introduces CV-IOT Gateway Module and Desktop Application

Retrieved on: 
Wednesday, May 31, 2023
CV, Temperature, NYSE, Electronics, Printed circuit board

By connecting the CV-IOT gateway to a Metcal Connection Validation™ (CV) soldering system and a computer or network, operations can utilize information on every joint to improve process control and efficiency in the soldering process.

Key Points: 
  • By connecting the CV-IOT gateway to a Metcal Connection Validation™ (CV) soldering system and a computer or network, operations can utilize information on every joint to improve process control and efficiency in the soldering process.
  • A standard handheld barcode scanner can easily be added to the setup for board-level traceability.
  • "CV-IOT makes real-time process control and traceability simple," said Seerena Wright, Metcal Product Manager.
  • To ensure data security, the CV-IOT module plugs directly into the CV unit and the computer or network through a wired connection.

Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023

Retrieved on: 
Monday, May 22, 2023
Galapagos NV, ACR, Abstract, CV, CET, FIL, Isabella Tree, JAK, Safety, Risk, Doctor of Philosophy, Rheumatoid arthritis, Pain, European Alliance of Associations for Rheumatology, Euronext, MD, Patient, RWE, Filgotinib, EULAR, Congress, Disease, Pharmaceutical industry, Frankincense, Galápagos Islands, Immunology

“We are focused on advancing treatment options for chronic, debilitating immune-mediated diseases such as RA and are excited to present further analyses on filgotinib’s efficacy and safety profile at this year’s EULAR congress,” said Daniele D’Ambrosio, MD, PhD, Therapeutic Area Head, Immunology, at Galapagos.

Key Points: 
  • “We are focused on advancing treatment options for chronic, debilitating immune-mediated diseases such as RA and are excited to present further analyses on filgotinib’s efficacy and safety profile at this year’s EULAR congress,” said Daniele D’Ambrosio, MD, PhD, Therapeutic Area Head, Immunology, at Galapagos.
  • “Our presence at EULAR underscores our firm commitment to develop transformational therapies to improve the lives of patients around the world.”
    A number of abstracts will present trial data analyses on filgotinib, a once-daily oral preferential JAK-1 inhibitor, for the treatment of moderate to severe active RA.
  • Furthermore, Galapagos is hosting a symposium: “JAK to reality: seeking clarity in RA”, which will focus on key considerations when selecting treatments for RA patients, efficacy and safety of JAK inhibitors, and the practical use of JAK inhibitors in the treatment of RA patients.
  • Distinct treatment responses in patients with rheumatoid arthritis receiving filgotinib 200 mg over 12 months: A post hoc analysis of FINCH 1
    What trade-offs are acceptable to rheumatoid arthritis patients during treatment selection?

Bempedoic acid significantly reduces the risk of major adverse cardiovascular events, and increased combination therapies can help more patients achieve LDL-C goals — late breaking EAS data

Retrieved on: 
Tuesday, May 23, 2023
Pharmaceutical, Health, Clinical Trials, Cardiology, EAS, CV, Myocardial infarction, Lipid, Cardiovascular disease, ATP, Splenic infarction, RRR, CVD, Agent handling, Incidence, Public health, Patient, Standard of care, Physician, Risk, Guideline, Daiichi Sankyo, Disease, Mortality, Principal, ESC, ACL, Therapy, Death, Imperial College London, Pharmaceutical industry, Dietary supplement

Both studies were presented in a late-breaker session at the 91st European Atherosclerosis Society congress.

Key Points: 
  • Both studies were presented in a late-breaker session at the 91st European Atherosclerosis Society congress.
  • Nearly 80% of patients who are at high- or very high-risk of CV events in Europe do not attain the guideline-recommended LDL-C goals, putting them at high risk of suffering an acute and often life-threatening cardiovascular event.
  • The CLEAR Outcomes trial answers those remaining questions and shows that bempedoic acid reduces the risk of major cardiovascular events in patients at high- and very high-risk.
  • We now know that, as an additional treatment option, bempedoic acid can not only help patients reach their guideline LDL-C recommendations but also lower their CV risk.

New urban health 'accelerator' aims to transform cardiovascular population health globally

Retrieved on: 
Monday, May 22, 2023
Blood pressure, Workforce, Male, Cardiovascular disease, CV, Stroke, Public, Workplace, World Health Assembly, Health, Splenic infarction, Hypertension, Death, Risk, Novartis Foundation, IntraHealth International, Accelerator, City, WHO, Paulo, World Health Organization, Pharmaceutical industry

The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.

Key Points: 
  • The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.
  • Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world's leading cause of death, according to the World Health Organization (WHO)1.
  • The accelerator aims to replicate CARDIO4Cities, the cardiovascular (CV) population health approach pioneered and validated by the Novartis Foundation, in 30 major cities within the next three years.
  • As a neutral broker between city governments, health experts, industry, implementing partners, funders and investors, the accelerator pledges the global community to direct action and funding toward transforming CV population health and equity.

New urban health 'accelerator' aims to transform cardiovascular population health globally

Retrieved on: 
Monday, May 22, 2023
Blood pressure, Workforce, Male, Cardiovascular disease, CV, Stroke, Public, Workplace, World Health Assembly, Health, Splenic infarction, Hypertension, Death, Risk, Novartis Foundation, IntraHealth International, Accelerator, City, WHO, Paulo, World Health Organization, Pharmaceutical industry

The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.

Key Points: 
  • The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.
  • Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world's leading cause of death, according to the World Health Organization (WHO)1.
  • The accelerator aims to replicate CARDIO4Cities, the cardiovascular (CV) population health approach pioneered and validated by the Novartis Foundation, in 30 major cities within the next three years.
  • As a neutral broker between city governments, health experts, industry, implementing partners, funders and investors, the accelerator pledges the global community to direct action and funding toward transforming CV population health and equity.

Syntiant’s Deep Learning Computer Vision Models Deployed on Renesas RZ/V2L Microprocessor

Retrieved on: 
Friday, May 19, 2023
Renesas Electronics, CV, Deep learning, 3D, POS, Intelligence, MPU, Santa Clara Convention Center, CPU, Algorithm, Workload, SDK, Video game

Designed for edge devices and optimized to reduce latency and memory footprint, Syntiant’s hardware-agnostic deep learning models can be used for multiple vision-based applications such as object detection, face recognition, pose estimation, background subtraction and image classification.

Key Points: 
  • Designed for edge devices and optimized to reduce latency and memory footprint, Syntiant’s hardware-agnostic deep learning models can be used for multiple vision-based applications such as object detection, face recognition, pose estimation, background subtraction and image classification.
  • “Our ongoing collaboration with the team at Syntiant now includes integrating their computer vision models into our DRP-AI accelerator core for enhanced AI vision processing,” said Shigeki Kato, vice president of the Enterprise Infrastructure Business Division at Renesas.
  • Models are further optimized to verify performance and reliability​ for high performance across numerous industries, ranging from smart home to retail analytics.
  • Demonstrations of the Syntiant and Renesas RZ/V2L combined solution will occur May 22-24 at the Renesas booth (#403) during the 2023 Embedded Vision Summit at the Santa Clara Convention Center.

Governor Ganjar Pranowo releases Indonesian MSME product for export, valued at IDR7billion

Retrieved on: 
Tuesday, May 16, 2023
2013 Central Java gubernatorial election, IDR, Food, CV, MSME, USD, Government, Republic, Local government, Banyumas Regency, MSME-Champions, Ratna, Publishers' Licensing Services, Ganjar, News, Coffee, Rail freight transport

4 containers of MSME product were released in Purwokerto, Central Java Province, while 3 containers were dispatched from Purbalingga and Pati.

Key Points: 
  • 4 containers of MSME product were released in Purwokerto, Central Java Province, while 3 containers were dispatched from Purbalingga and Pati.
  • The 7 containers of export products included essential oils, organic coconut sugar, processed foods, brooms, organic palm sugar, and handicrafts.
  • Central Java Governor Ganjar Pranowo released seven containers of local MSME product for export to Asia, the Middle East and America.
  • Following the export release, Governor Ganjar Pranowo stated that the support provided by the local government and MSME activists had yielded results.

GumGum's Accredited Contextual Solution, Verity™, Selected As Newest Contextual Vendor by MediaMath

Retrieved on: 
Tuesday, May 16, 2023
Natural language processing, CV, DSP, CTV, MRC, NLP, Media Rating Council, Ecosystem, Mobile phone, Online shopping, Verity

SANTA MONICA, Calif., May 16, 2023 /PRNewswire-PRWeb/ -- GumGum, a contextual-first, global digital advertising platform, today announced that its leading contextual intelligence solution, Verity, will now be available in MediaMath's demand-side platform (DSP) as the first MRC content-level accredited partner.

Key Points: 
  • Advertisers can now take a mindset-first approach across their programmatic campaigns within the MediaMath platform with GumGum Verity.
  • By applying Verity's accredited and advanced technology, advertisers are able to align their ad contextually with relevant content.
  • "We're thrilled to integrate with MediaMath and expand Verity's footprint to another leading DSP," said Hailey Denenberg, interim Head of VerityTM.
  • "We are excited to make the only MRC-accredited contextual provider for content-level analysis, GumGum Verity, available to our clients through the MediaMath platform," said Dawn Valandra, Director of Ecosystem Activation at MediaMath.

Workhorse Group Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 15, 2023
ACT, EV, CV, Q3, U.S. Department of Defense Strategy for Operating in Cyberspace, FedEx Ground, Farmer, FALCON, Green, Grand Forks, North Dakota, W56, Draft horse, Growth, Government, United States Department of the Air Force, Research, Airline, Warehouse, Mobile phone, Beauty salon, Air cargo, Pharmaceutical industry, Aerospace

CINCINNATI, May 15, 2023 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS ) (“Workhorse” or “the Company”), an American technology company with a vision to pioneer the transition to zero emission commercial vehicles, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • CINCINNATI, May 15, 2023 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS ) (“Workhorse” or “the Company”), an American technology company with a vision to pioneer the transition to zero emission commercial vehicles, today reported financial results for the first quarter ended March 31, 2023.
  • We are making steady progress in expanding our CV dealer network and plan to onboard 8-10 new dealers in 2023.
  • Workhorse will focus on prototype design, test, and build in 2023 and 2024 with production planned to begin 2025.
  • Workhorse is reaffirming its outlook and expects to generate between $75-125 million in revenue in 2023.